News & Events

News


Thursday August 03, 2017

Neurocrine Biosciences Reports Second Quarter 2017 Results

- INGREZZA® Net Product Sales of $6.3 Million in Initial Two Months of Commercialization as the First and Only U.S. Food and Drug Administration Approved Product for the Treatment of Tardive Dyskinesia - Partner AbbVie Expected to Submit Elagolix NDA for Endometriosis During the Third Quarter of 2017 and Pay $30 Million Milestone in Fourth Quarter of 2017 - Partner Mitsubishi Tanabe Expected to Initiate Pivotal Trial of INGREZZA in Asia for the Treatment of Tardive Dyskinesia and Pay $15 Million in Milestones during Third Quarter of 2017 - Completed Offering of $517.5 Million Convertible Senior Notes Due 2024 SAN DIEGO, Aug. 3, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASD...


Friday July 28, 2017

Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2017 Results

Conference Call and Webcast Scheduled for August 3, 2017 SAN DIEGO, July 28, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company will report second quarter 2017 results after the Nasdaq market close on August 3, 2017.  Neurocrine will then host a live conference call and webcast to discuss its financial results and provide a Company update that day at 5:00pm Eastern Time (2:00pm Pacific Time). Participants can access the live conference call by dialing 888-632-3381 (US) or 785-424-1678 (International) using the conference ID: NBIX. The call can also be accessed via the webcast through the Company's website at http://www.neurocrine.com. I...


Friday July 21, 2017

Neurocrine Biosciences Announces the Appointment of Julie Cooke as Chief People Officer

SAN DIEGO, July 21, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX), a biotechnology company focused on neurological and endocrine related disorders, announced that Julie Cooke is joining as Chief People Officer in September 2017 and will be a member of the Management Committee.   "Neurocrine is delighted to welcome Julie Cooke as our Chief People Officer to lead our Human Resource function," said David-Alexandre C. Gros, President and Chief Operating Officer of Neurocrine Biosciences. "Julie's deep and broad experience across all aspects of human resources will be tremendously valuable as we grow and continue to expand our capabilities while remaining true to the culture...


Friday June 09, 2017

Neurocrine Biosciences to Present at the Goldman Sachs 38th Annual Global Healthcare Conference

Live Audio Webcast Will be on June 15, 2017 SAN DIEGO, June 9, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, CEO of Neurocrine Biosciences, will be presenting at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA. The live presentation takes place on Thursday, June 15 at 9:20am PT (12:20pm ET).  The presentation will be webcast and may be accessed on the Company's website at http://www.neurocrine.com.   Listeners are encouraged to visit the website approximately 5 minutes prior to the presentation to download or install any necessary software.  A replay of the presentation will be available on ...


Friday June 02, 2017

Neurocrine Announces Presentations Related to INGREZZA® (valbenazine) Capsules at the 21st International Congress of Parkinson's Disease and Movement Disorders

SAN DIEGO, June 2, 2017 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today the upcoming presentation of three posters at the 21st International Congress of Parkinson's Disease and Movement Disorders (MDS), including data from the KINECT 3 Phase III extension study of INGREZZA® (valbenazine) capsules for the treatment of adults with tardive dyskinesia (TD). The 21st International Congress of Parkinson's Disease and Movement Disorders will take place in Vancouver BC, Canada from June 4-8, 2017. Neurocrine's three posters will be presented on Tuesday, June 6, 2017 from 13:45 - 15:15 PDT: 399: Low Incidence of Extrapyramidal Symptoms in Subjects with Tardive Dys...

Events